Sinovac Named to Zhongguancun's Top 20 Most Influential Brands
22 Dezembro 2008 - 11:00AM
PR Newswire (US)
BEIJING, Dec. 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE
Alternext US: SVA), a leading provider of vaccines in China, today
announced that it was recognized as one of Zhongguancun's Top 20
Most Influential Brands. 2008 marks only the 30th anniversary of
China's reform and market liberation program along with the 20th
anniversary of the establishment of the Zhongguancun, a technology
hub situated in Beijing that is often referred to as "China's
Silicon Valley". The Beijing municipal government recognizes the
importance of advancing the development of this technology district
that consists of more than 800 companies that contribute
approximately 18% of Beijing's GDP. This year, the Beijing
municipal government conducted a comprehensive study of experiences
and developments within the Zhongguancun district for the last 20
years and named twenty leading technology companies to be the "Top
20 Most Influential Brands". Sinovac and other leading technology
companies such as Sina, Lenovo, Aigo, Sohu and New Oriental were
the recipients of this prestigious recognition. The award ceremony
was held by the Administrative Committee of the Zhongguancun
Science Park and was entitled, "Haidian Tells the World -
Celebration of the 30th Anniversary of Reform and Liberalization,
Celebration of the 20th Anniversary of the Foundation of
Zhongguancun Science Park". Mr. Weidong Yin, Chairman, President
and CEO of Sinovac Biotech Ltd., commented, "We are pleased to be
named as one of the most influential brands within the Beijing's
high technology development zone. This recognition is a testament
to Sinovac's commitment to providing comprehensive marketing and
sales programs that support our brand in China. In addition, our
vaccine research and development capabilities have enabled us to
successfully commercialize three vaccines and continue to cultivate
our development pipeline." About Sinovac Sinovac Biotech Ltd. is a
China-based biopharmaceutical company that focuses on the research,
development, manufacture and commercialization of vaccines that
protect against human infectious diseases. Sinovac's commercialized
vaccines include Healive(R) (hepatitis A), Bilive(R) (combined
hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1).
Sinovac is currently developing Universal Pandemic Influenza
vaccine and Japanese encephalitis vaccine. Additional information
about Sinovac is available on its website, http://www.sinovac.com/
. To be added to our distribution list, please email: . For more
information, please contact: Helen G. Yang Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email:
Investors/Media: Stephanie Carrington/Janine McCargo The Ruth Group
Tel: +1-646-536-7017/7033 Email: DATASOURCE: Sinovac Biotech Ltd.
CONTACT: Helen G. Yang, Sinovac Biotech Ltd., Tel: +86-10-8289-0088
x871, Fax: +86-10-6296-6910 or ; or Investors-Media: Stephanie
Carrington or Janine McCargo, The Ruth Group, +1-646-536-7017 7033,
or and Web site: http://www.sinovac.com/
Copyright